Lucid Capital initiated Buy coverage on Ovid Therapeutics, noting that AI stocks generally offer greater upside potential.
1 report, 1 independent
Updated Aug 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lucid Capital initiated Buy coverage on Ovid Therapeutics, noting that AI stocks generally offer greater upside potential.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ovid Therapeutics (United States)
company in New York, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target Ovid Therapeutics Inc. (NASDAQ:OVID) is among the best US stocks under $10 to invest in. Analysts at Lucid Capital have